Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2489人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866472, encodeId=28e718664e2d0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, objectType=article, longId=294803, objectId=6aaf29480333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aaf29480333, replyNumber=0, likeNumber=74, createdTime=2022-04-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aaf29480333, moduleTitle=J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aaf29480333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866507, encodeId=92bc186650eca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=62, createdTime=2023-01-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866513, encodeId=34e018665133e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌, objectType=article, longId=295668, objectId=63ef2956689c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ef2956689c, replyNumber=0, likeNumber=91, createdTime=2022-12-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ef2956689c, moduleTitle=Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ef2956689c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866498, encodeId=ecd2186649826, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：诊断非小细胞鳞状细胞肺癌的生物标志物大PK！, objectType=article, longId=295319, objectId=2f16295319e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f16295319e5, replyNumber=0, likeNumber=63, createdTime=2022-06-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f16295319e5, moduleTitle=Ther Adv Med Oncol：诊断非小细胞鳞状细胞肺癌的生物标志物大PK！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f16295319e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866313, encodeId=f0bb1866313a8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, objectType=article, longId=219179, objectId=3d182191e9b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d182191e9b7, replyNumber=0, likeNumber=101, createdTime=2021-11-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d182191e9b7, moduleTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d182191e9b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866309, encodeId=c04c186630961, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, objectType=article, longId=219118, objectId=d4b221911890, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4b221911890, replyNumber=0, likeNumber=62, createdTime=2022-03-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4b221911890, moduleTitle=Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4b221911890)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866478, encodeId=127518664e886, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：第8版IB期NSCLC术后辅助化疗可改善患者预后, objectType=article, longId=295061, objectId=feba295061c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=feba295061c5, replyNumber=0, likeNumber=67, createdTime=2022-03-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=feba295061c5, moduleTitle=Front Oncol：第8版IB期NSCLC术后辅助化疗可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=feba295061c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866470, encodeId=608318664e010, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：真实世界数据研究新诊断转移性女性乳腺癌患者中年轻（≦40岁）患者的治疗以及预后, objectType=article, longId=294720, objectId=68eb294e203d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68eb294e203d, replyNumber=0, likeNumber=83, createdTime=2022-05-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68eb294e203d, moduleTitle=Ther Adv Med Oncol：真实世界数据研究新诊断转移性女性乳腺癌患者中年轻（≦40岁）患者的治疗以及预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68eb294e203d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866305, encodeId=8ae118663050b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, objectType=article, longId=219072, objectId=03b82190e28e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03b82190e28e, replyNumber=0, likeNumber=76, createdTime=2022-03-25, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03b82190e28e, moduleTitle=Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03b82190e28e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866426, encodeId=ba8a1866426ee, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, objectType=article, longId=292661, objectId=f0b9292661bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b9292661bc, replyNumber=0, likeNumber=43, createdTime=2022-12-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b9292661bc, moduleTitle=Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b9292661bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866485, encodeId=843518664850e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=65, createdTime=2022-06-23, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866312, encodeId=ba92186631207, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, objectType=article, longId=219161, objectId=aee8219161b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aee8219161b7, replyNumber=0, likeNumber=93, createdTime=2021-11-09, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aee8219161b7, moduleTitle=Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aee8219161b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866462, encodeId=f506186646277, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, objectType=article, longId=294238, objectId=ea07294238cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea07294238cf, replyNumber=0, likeNumber=63, createdTime=2022-11-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea07294238cf, moduleTitle=J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea07294238cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866221, encodeId=29dd186622169, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响, objectType=article, longId=217140, objectId=67cd21e14003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67cd21e14003, replyNumber=0, likeNumber=80, createdTime=2022-07-28, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67cd21e14003, moduleTitle=J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67cd21e14003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866298, encodeId=562e1866298e5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle= J Hematol Oncol：多发性骨髓瘤患者对COVID-19 mRNA接种的反应是保守但受损的, objectType=article, longId=218812, objectId=432c2188125f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=432c2188125f, replyNumber=0, likeNumber=73, createdTime=2021-12-08, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=432c2188125f, moduleTitle= J Hematol Oncol：多发性骨髓瘤患者对COVID-19 mRNA接种的反应是保守但受损的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=432c2188125f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866524, encodeId=a1fb186652418, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=95, createdTime=2022-06-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866607, encodeId=8952186660e3e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, objectType=article, longId=727471, objectId=cd20e27471d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd20e27471d6, replyNumber=0, likeNumber=80, createdTime=2022-10-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd20e27471d6, moduleTitle=J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd20e27471d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866451, encodeId=24991866451e4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncology：久坐不动，大大增加癌症患者的死亡风险, objectType=article, longId=293649, objectId=a9a529364953, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9a529364953, replyNumber=0, likeNumber=73, createdTime=2022-01-18, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9a529364953, moduleTitle=JAMA Oncology：久坐不动，大大增加癌症患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9a529364953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866646, encodeId=ec381866646fb, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤, objectType=article, longId=730250, objectId=b725e302503d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b725e302503d, replyNumber=0, likeNumber=71, createdTime=2023-01-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b725e302503d, moduleTitle=JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b725e302503d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866340, encodeId=0199186634080, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, objectType=article, longId=220048, objectId=533b22004862, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=533b22004862, replyNumber=0, likeNumber=0, createdTime=2022-08-15, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=533b22004862, moduleTitle=Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=533b22004862)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：派姆单抗治疗不稳定性高的晚期子宫内膜癌的疗效

2022-04-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2023-01-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：Sugemalimab联合含铂化疗一线治疗转移性非小细胞肺癌

2022-12-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：诊断非小细胞鳞状细胞肺癌的生物标志物大PK！

2022-06-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效

2021-11-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：真实世界中曲妥珠单抗生物仿制剂CT-P6在HER2阳性早期（EBC）和转移性乳腺癌（MBC）患者中的疗效

2022-03-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：第8版IB期NSCLC术后辅助化疗可改善患者预后

2022-03-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：真实世界数据研究新诊断转移性女性乳腺癌患者中年轻（≦40岁）患者的治疗以及预后

2022-05-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：吡咯替尼联合长春瑞滨治疗HER2阳性转移性乳腺癌的疗效:多中心回顾性研究

2022-03-25

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：ECHELON-2研究更新数据表明，A+CHP较CHOP持续改善CD30+外周T细胞淋巴瘤(PTCL)患者的预后

2022-12-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-06-23

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：CDKI联合氟维司群有望成为激素受体阳性、HER2阴性的晚期乳腺癌的标准治疗方案！

2021-11-09

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：Lorlatinib（劳拉替尼）治疗ALK+ NSCLC患者进展后继续使用仍然有效

2022-11-20

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：卡培他滨维持 vs 治疗中断对一线治疗后病情稳定的转移性结直肠癌患者预后和生活质量的影响

2022-07-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Hematol Oncol：多发性骨髓瘤患者对COVID-19 mRNA接种的反应是保守但受损的

2021-12-08

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-06-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：新辅助化疗联合纳武单抗治疗可切除IIIA期非小细胞肺癌的3年预后

2022-10-21

医者仁心 (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncology：久坐不动，大大增加癌症患者的死亡风险

2022-01-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：DDGP方案 vs SMILE方案治疗新诊断的局部晚期结外自然杀伤/T细胞淋巴瘤

2023-01-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：PD1抑制剂penpulimab联合安罗替尼一线治疗中国不可切除肝细胞癌（uHCC）患者的疗效和安全性

2022-08-15

科室
- - 订阅+
  - 更多科室
工具
服务